BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35647204)

  • 1. Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer.
    Guo Y; Yang N; Li G; Yin X; Dong L
    J Immunol Res; 2022; 2022():4379216. PubMed ID: 35647204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis.
    Zeng Q; Yi C; Lu J; Wang X; Chen K; Hong L
    Cancer Med; 2023 Apr; 12(7):9024-9040. PubMed ID: 36708070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian carcinoma immune-related microRNA affects the heterogeneity of the endocrine microenvironment and anti-tumor immune pattern.
    Gao K; Wang Q; Xiang P; Xiong J; Xu X; Qin L; Sun X; Fan Y; Yue C
    J Gene Med; 2024 Jan; 26(1):e3602. PubMed ID: 37813677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
    Park J; Park SY; Kim JH
    Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
    Xue B; Li S; Jin X; Liu L
    BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
    Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
    Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
    Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level.
    Kielbik M; Szulc-Kielbik I; Klink M
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
    Zheng L; Li L; Lu Y; Jiang F; Yang XA
    Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer.
    Feng X; Li L; Wang L; Luo S; Bai X
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
    Zhang L; Chen Y; Li F; Bao L; Liu W
    Front Immunol; 2019; 10():867. PubMed ID: 31105696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
    Masanek U; Stammler G; Volm M
    Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
    Niu L; Ni H; Hou Y; Du Q; Li H
    Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.